John S. Yu - 08 Oct 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Reporting relationship: CEO and Chairman, Director, 10%+ Owner
Issuer ticker: KAPA
Reported as of: 08 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Nov 2025, 17:24:11 UTC
Prior SEC filing: 24 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ John S Yu

Key filing fact

John S. Yu filed Form 4 for Kairos Pharma, LTD. (KAPA) on 26 Nov 2025.

Key facts

This page summarizes John S. Yu's Form 4 filing for Kairos Pharma, LTD. (KAPA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Nov 2025, 17:24.

Change

Previous filing in this sequence was filed on 24 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001550545 Primary reporting owner

Yu John S

Relationship: CEO and Chairman, Director, 10%+ Owner
Address: C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES
Signature: /s/ John S Yu
Signature date: 26 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KAPA transaction

COMMON STOCK

Award

Transaction value: $0
Shares: +190,840
Change %: +486%
Price: $0.000000
Shares after: 230,105
Date: 08 Oct 2025
Ownership: Direct
Footnotes: F1, F2

KAPA holding

COMMON STOCK

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,316,572
Date: 08 Oct 2025
Ownership: By Self as Trustee for The Yu Family Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date.

Footnote F2

Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting.